PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Zhou, Q.* ; Mareljic, N.* ; Michaelsen, M.* ; Parhizkar, S.* ; Heindl, S.* ; Nuscher, B.* ; Farny, D.* ; Czuppa, M.* ; Schludi, C.* ; Graf, A.* ; Krebs, S.* ; Blum, H.* ; Feederle, R. ; Roth, S.* ; Haass, C.* ; Arzberger, T.* ; Liesz, A.* ; Edbauer, D.*

Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model.

EMBO Mol. Med. 12:e10919 (2020)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The C9orf72 repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD). Non-canonical translation of the expanded repeat results in abundant poly-GA inclusion pathology throughout the CNS. (GA)(149)-CFP expression in mice triggers motor deficits and neuroinflammation. Since poly-GA is transmitted between cells, we investigated the therapeutic potential of anti-GA antibodies by vaccinating (GA)(149)-CFP mice. To overcome poor immunogenicity, we compared the antibody response of multivalent ovalbumin-(GA)(10) conjugates and pre-aggregated carrier-free (GA)(15). Only ovalbumin-(GA)(10) immunization induced a strong anti-GA response. The resulting antisera detected poly-GA aggregates in cell culture and patient tissue. Ovalbumin-(GA)(10) immunization largely rescued the motor function in (GA)(149)-CFP transgenic mice and reduced poly-GA inclusions. Transcriptome analysis showed less neuroinflammation in ovalbumin-(GA)(10)-immunized poly-GA mice, which was corroborated by semiquantitative and morphological analysis of microglia/macrophages. Moreover, cytoplasmic TDP-43 mislocalization and levels of the neurofilament light chain in the CSF were reduced, suggesting neuroaxonal damage is reduced. Our data suggest that immunotherapy may be a viable primary prevention strategy for ALS/FTD in C9orf72 mutation carriers.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.821
2.057
15
21
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Amyotrophic Lateral Sclerosis ; C9orf72 ; Frontotemporal Dementia ; Immunotherapy ; Neurodegeneration; Dipeptide-repeat Proteins; To-cell Transmission; Alpha-synuclein; Hexanucleotide Repeat; Cerebrospinal-fluid; Alzheimers-disease; Kappa-b; Tau; Pathology; Immunotherapy
Sprache englisch
Veröffentlichungsjahr 2020
Prepublished im Jahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Zeitschrift EMBO Molecular Medicine
Quellenangaben Band: 12, Heft: 2, Seiten: , Artikelnummer: e10919 Supplement: ,
Verlag Wiley
Verlagsort Chichester
Begutachtungsstatus Peer reviewed
Institut(e) CF Monoclonal Antibodies (CF-MAB)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502210-001
DOI 10.15252/emmm.201910919
WOS ID WOS:000503443600001
Scopus ID 85077029485
PubMed ID 31858749
Erfassungsdatum 2020-01-10
[➜Korrektur melden]